Screening for depression in children and adolescents

US Preventive Services Task Force recommendation statement

On behalf of the US Preventive Services Task Force

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

DESCRIPTION: This article describes the update of the 2009 US Preventive Services Task Force (USPSTF) recommendation on screening for major depressive disorder (MDD) in children and adolescents. METHODS: The USPSTF reviewed the evidence on the benefits and harms of screening, accuracy of primary care-feasible screening tests, and benefits and harms of treatment with psychotherapy, medications, and collaborative care models in patients aged 7 to 18 years. POPULATION: This recommendation applies to children and adolescents aged ≤ 18 years who do not have an MDD diagnosis. RECOMMENDATION: The USPSTF recommends screening for MDD in adolescents aged 12 to 18 years. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up (B recommendation). The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for MDD in children aged ≤11 years (I statement).

Original languageEnglish (US)
Article numbere20154467
JournalPediatrics
Volume137
Issue number3
DOIs
StatePublished - Mar 1 2016
Externally publishedYes

Fingerprint

Major Depressive Disorder
Advisory Committees
Depression
Psychotherapy
Primary Health Care
Therapeutics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Screening for depression in children and adolescents : US Preventive Services Task Force recommendation statement. / On behalf of the US Preventive Services Task Force.

In: Pediatrics, Vol. 137, No. 3, e20154467, 01.03.2016.

Research output: Contribution to journalArticle

On behalf of the US Preventive Services Task Force. / Screening for depression in children and adolescents : US Preventive Services Task Force recommendation statement. In: Pediatrics. 2016 ; Vol. 137, No. 3.
@article{9ce36150ed254c718eb16c0772692522,
title = "Screening for depression in children and adolescents: US Preventive Services Task Force recommendation statement",
abstract = "DESCRIPTION: This article describes the update of the 2009 US Preventive Services Task Force (USPSTF) recommendation on screening for major depressive disorder (MDD) in children and adolescents. METHODS: The USPSTF reviewed the evidence on the benefits and harms of screening, accuracy of primary care-feasible screening tests, and benefits and harms of treatment with psychotherapy, medications, and collaborative care models in patients aged 7 to 18 years. POPULATION: This recommendation applies to children and adolescents aged ≤ 18 years who do not have an MDD diagnosis. RECOMMENDATION: The USPSTF recommends screening for MDD in adolescents aged 12 to 18 years. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up (B recommendation). The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for MDD in children aged ≤11 years (I statement).",
author = "{On behalf of the US Preventive Services Task Force} and Siu, {Albert L.} and Kirsten Bibbins-Domingo and Grossman, {David C.} and Baumann, {Linda Ciofu} and Davidson, {Karina W.} and Mark Ebell and Garc{\'i}a, {Francisco A R} and Matthew Gillman and Jessica Herzstein and Kemper, {Alex R.} and Krist, {Alex H.} and Kurth, {Ann E.} and Owens, {Douglas K.} and Phillips, {William R.} and Phipps, {Maureen G.} and Pignone, {Michael P.}",
year = "2016",
month = "3",
day = "1",
doi = "10.1542/peds.2015-4467",
language = "English (US)",
volume = "137",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "3",

}

TY - JOUR

T1 - Screening for depression in children and adolescents

T2 - US Preventive Services Task Force recommendation statement

AU - On behalf of the US Preventive Services Task Force

AU - Siu, Albert L.

AU - Bibbins-Domingo, Kirsten

AU - Grossman, David C.

AU - Baumann, Linda Ciofu

AU - Davidson, Karina W.

AU - Ebell, Mark

AU - García, Francisco A R

AU - Gillman, Matthew

AU - Herzstein, Jessica

AU - Kemper, Alex R.

AU - Krist, Alex H.

AU - Kurth, Ann E.

AU - Owens, Douglas K.

AU - Phillips, William R.

AU - Phipps, Maureen G.

AU - Pignone, Michael P.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - DESCRIPTION: This article describes the update of the 2009 US Preventive Services Task Force (USPSTF) recommendation on screening for major depressive disorder (MDD) in children and adolescents. METHODS: The USPSTF reviewed the evidence on the benefits and harms of screening, accuracy of primary care-feasible screening tests, and benefits and harms of treatment with psychotherapy, medications, and collaborative care models in patients aged 7 to 18 years. POPULATION: This recommendation applies to children and adolescents aged ≤ 18 years who do not have an MDD diagnosis. RECOMMENDATION: The USPSTF recommends screening for MDD in adolescents aged 12 to 18 years. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up (B recommendation). The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for MDD in children aged ≤11 years (I statement).

AB - DESCRIPTION: This article describes the update of the 2009 US Preventive Services Task Force (USPSTF) recommendation on screening for major depressive disorder (MDD) in children and adolescents. METHODS: The USPSTF reviewed the evidence on the benefits and harms of screening, accuracy of primary care-feasible screening tests, and benefits and harms of treatment with psychotherapy, medications, and collaborative care models in patients aged 7 to 18 years. POPULATION: This recommendation applies to children and adolescents aged ≤ 18 years who do not have an MDD diagnosis. RECOMMENDATION: The USPSTF recommends screening for MDD in adolescents aged 12 to 18 years. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up (B recommendation). The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for MDD in children aged ≤11 years (I statement).

UR - http://www.scopus.com/inward/record.url?scp=84960193074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960193074&partnerID=8YFLogxK

U2 - 10.1542/peds.2015-4467

DO - 10.1542/peds.2015-4467

M3 - Article

VL - 137

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 3

M1 - e20154467

ER -